A Multinational Comparison of Anti–Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific

2019 ◽  
Vol 3 (1) ◽  
pp. 16-26 ◽  
Author(s):  
Ravi Parikh ◽  
Nathan Pirakitikulr ◽  
Jay Chhablani ◽  
Yoichi Sakurada ◽  
Rishi P. Singh ◽  
...  
Keyword(s):  
United States ◽  
Vascular Endothelial Growth Factor ◽  
United Kingdom ◽  
Growth Factor ◽  
The United States ◽  
Asia Pacific ◽  
Vascular Endothelial ◽  
The United Kingdom ◽  
Endothelial Growth Factor

scholarly journals The recent advances in Vascular endothelial growth factor and metabolic syndrome in prostate cancer

2021 ◽  
Vol 5 (1) ◽  
pp. 13-18
Author(s):  
Ya-nan Zhou ◽  
Jin-qi Song ◽  
Gang-liang Tu ◽  
Hui Xu ◽  
Meng Ding
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Metabolic Syndrome ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
The United States ◽  
Epidemiological Studies ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Diet And Lifestyle

Prostate cancer is one of the most common male malignant tumors in Western countries. In the United States, there are about 170,000 new cases of prostate cancer in 2019, ranking second only to lung cancer.1, 2 In recent years, the incidence of prostate cancer in China is gradually increasing occupying the third place among male urogenital malignancies. The metastasis of prostate cancer mainly depends on blood vessels and lymphatic vessels, and the late discovery and poor prognosis of patients are the main reasons for the high fatality rate.2 Relevant epidemiological studies on immigration have found that the incidence of PCa in The Asian population in the United States is as high as 77.8 / l0000, which is similar to local residents and significantly higher than that in the native population in Asia. This suggests that, in addition to race and family history, different diet and lifestyle in China and the West may play an important role in the development and progression of PCa.3 Epidemiological studies have shown an association between geographic location and prostate cancer risk. In fact, the incidence of prostate cancer in Western men is 15 times higher than in Asian men. This suggests that environmental factors or lifestyle, especially diet and nutrition, may play a key role in the occurrence and development of prostate cancer.4 To some extent, metabolic syndrome reflects the diet and lifestyle of patients and is closely related to the occurrence and development of prostate cancer. In addition, Vascular endothelial growth factor (VEGF) as a kind of multi functional cytokine works through specific role in endothelial cells.It can promote endothelial cell proliferation, migration, and increase Vascular permeability. And VEGF can be induced in the body for blood vessel growth, angiogenesis, is closely related to tumorigenesis and metastasis. Numerous recent studies have shown that VEGF is closely related to the occurrence and development of prostate cancer and metabolic syndrome.5 In this paper, multiple physiological and pathological mechanisms of VEGF and metabolic syndrome associated with prostate cancer are reviewed. 

scholarly journals Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: Basics for Primary Care Providers

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Carmen P. Escalante ◽  
Ali Zalpour
Keyword(s):  
Primary Care ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Drug Class ◽  
Primary Care Providers ◽  
The United States ◽  
Vascular Endothelial ◽  
Care Providers ◽  
Vegf Inhibitors ◽  
Endothelial Growth Factor

Frequently, primary care providers continue to manage the overall medical care of cancer patients. With newer and often more potent antitumor agents, patients may present to their local physicians with drug-induced toxicities such as hypertension induced by vascular endothelial growth factor (VEGF) inhibitors. It is imperative that these healthcare providers are aware of basic aspects of this drug class, as its use has increased significantly in the last several years. Uncontrolled or malignant hypertension due to these agents should be recognized readily and treated early to prevent more severe outcomes. This overview provides a brief background on the role of VEGF and angiogenesis in tumor metabolism as well as theories of the mechanism of VEGF inhibitors and hypertension. Helpful clinical practice aspects including the types of inhibitors used in the United States and their pharmacologic characteristics will be discussed. Also, diagnosis and treatment of hypertension induced by vascular endothelial growth factors are reviewed. A summary of key aspects of this drug class and hypertension is included.

scholarly journals Differential expression of transcripts from the gene encoding the vascular endothelial growth factor D, FIGF, in non-small cell lung cancer and association with patient survival.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Vascular Endothelial ◽  
Small Cell Lung ◽  
Endothelial Growth Factor

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States (1). We mined published microarray data (2, 3, 4) to identify differentially expressed genes in NSCLC. We found three transcripts produced by the FIGF gene - a FIGF transcript and two read-through transcripts containing sequences from FIGF and a neighboring gene, PIR (PIR-FIGF) - among those whose expression was most quantitatively different in human NSCLC tumors as compared to the lung. FIGF and PIR-FIGF expression levels were significantly decreased in NSCLC tumors as compared to the lung, and lower expression of FIGF in patient tumors was significantly associated with worse overall survival. Vascular endothelial growth factor D may be important for initiation or progression of non-small cell lung cancer in humans.

Divided Action

2019 ◽  
pp. 134-155
Author(s):  
Thomas K. Robb ◽  
David James Gill
Keyword(s):  
United States ◽  
United Kingdom ◽  
New Zealand ◽  
Strategic Alliance ◽  
The United States ◽  
Asia Pacific ◽  
The United Kingdom ◽  
Security Planning ◽  
Military Support ◽  
British Commonwealth

This chapter looks at how, throughout 1954, the United States began to consider seriously the creation of a wider strategic alliance in the Asia-Pacific that would include the United Kingdom, Australia, and New Zealand. Such a policy reversal reflected growing concerns about Communist expansion in Southeast Asia. The United States consequently looked abroad for support for collective action. Only a small number of states, however, could provide substantial military resources. Washington focused its attention on London, Canberra, and Wellington. Fundamental disagreements among all four states concerning Cold War strategy persisted throughout negotiations. Although welcoming the opportunity for closer cooperation in the realm of security planning, the United Kingdom, Australia, and New Zealand all resisted U.S. ideas about immediate and major military commitments in the region. Even the existence of the ANZUS Treaty proved insufficient motivation for Canberra and Wellington to agree to support Washington's request for military support. The treaty instead appeared to have the opposite effect as antipodean officials feared the dilution or dissolution of existing trilateral strategic arrangements in favor of a wider alliance. All three British Commonwealth powers instead drove debate away from immediate military action toward longer-term alliance building.

Sign in / Sign up

Export Citation Format

Share Document